辉瑞新冠药服用注意事项？

During treatment with Pfizer's new coronavirus drug nematvir/ritonavir (Paxlovid), please note that this product should be taken as soon as possible within 5 days of COVID-19 diagnosis and the onset of symptoms. If a patient requires hospitalization due to severe or critical COVID-19 after starting treatment with this product, it is also recommended to complete 5 days of treatment. Pfizer's new coronavirus drug Nematvir/Ritonavir (Paxlovid) is used to treat coronavirus disease 2019 (COVID-19). It is targeted at adults who do not need supplemental oxygen and are at an increased risk of developing severe COVID-19 disease. There are still some matters that need to be paid attention to.

Pfizer's new coronavirus drug nematvir/ritonavir (Paxlovid) may interact with other drugs, resulting in serious risks, so review concomitant medications during treatment with this product and monitor patients for adverse reactions related to concomitant medication. Nematvir must be taken with ritonavir. If not administered with ritonavir, plasma levels of nematvir may be insufficient to achieve the desired therapeutic effect.

During the treatment of coronavirus disease 2019 (COVID-19), you should also pay attention to the following:

1. It should not be used in patients with severe renal impairment (eGFR<30 mL/min, including ESRD patients under hemodialysis). Use of this product in patients with severe renal impairment may result in overexposure and potential toxicity.

2. It should not be used in patients with severe liver damage. Pharmacokinetic and clinical data in patients with severe hepatic impairment are currently unavailable.

3. Patients with a history of liver disease, abnormal liver enzymes or hepatitis should use this product with caution. Elevated hepatic transaminases, clinically apparent hepatitis, and jaundice have occurred in patients receiving ritonavir.

4. Patients with uncontrolled or undiagnosed HIV-1 infection may be at risk of HIV-1 becoming resistant to HIV protease inhibitors if they take nematvir and ritonavir.

5. Patients with rare genetic diseases such as galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not use this product because nematvir tablets contain lactose.

6. Women of childbearing age should avoid becoming pregnant during the treatment of this product and for 7 days after the end of treatment. There are no data on the use of this product during pregnancy and the risk of drug-related adverse developmental outcomes is not known.

7. There is no data on the use of this product by pregnant women. This product should be used during pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus. It is recommended that patients read the drug instructions carefully before taking the medication and follow the doctor's instructions.

Recommended related articles: